News
Agilent Showcases ‘Consistent, Greener, Smarter’ Approach at Analytica 2022
Agilent Technologies Inc. (NYSE: A) today announced that it will showcase its latest workflows and solutions at Analytica 2022, being held 21 to 24 June 2022 in Munich, Germany.
“We are delighted
Humana Healthy Horizons Commits $4.6 Million to Improve Health of Ohioans
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced today that it has invested $4.6 million to support community organizations
Agilent Wins Multiple 2022 Scientists' Choice Awards at ASMS
Agilent Technologies Inc. (NYSE: A) announced that it has received three 2022 Scientists’ Choice Awards including Best New Spectroscopy Product of 2021. Announced at the 70th ASMS Conference on
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
Pfizer Inc. (NYSE: PFE) today shared data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) study evaluating the use of PAXLOVID™ (nirmatrelvir
Humana to Donate Downtown Louisville Office Building to UofL
Humana Inc. (NYSE: HUM) today announced that it will donate an office building in Downtown Louisville to the University of Louisville (UofL) in support of the activities of UofL’s Health Equity
Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!
Come chill with us! This week is Diabetes Awareness Week and DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (rt-CGM) for people with diabetes, is honouring
Pfizer Completes Acquisition of ReViral
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research
Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines
Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS)
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research
Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide
Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022
Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase its expanded global portfolio of real-time continuous glucose
Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the company will participate in the Goldman Sachs 43rd Annual Healthcare Conference on Wednesday, June 15, in Rancho Palos Verdes, California.
Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union
Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR
Pfizer Provides Update on Ownership Interest in Haleon
Pfizer Inc. (NYSE: PFE) today provided an update on its ownership interest in Haleon plc (Haleon), the newly independent company which will hold the joint Consumer Healthcare business of GSK plc
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 3:45 p.m. EDT on Monday, June 6, 2022, with Angela Hwang, Group President, Pfizer
Dexcom Issues Statement on Recent Market Speculation
DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation:
“Like many companies, Dexcom’s Board and management team regularly review
Agilent Announces Collaboration with APC on Real-Time Process Monitoring
Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique
Quidel and Ortho Announce Expected Closing of Ortho Transaction
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of